Literature DB >> 3286509

Ciprofloxacin and norfloxacin for selective decontamination in patients with severe granulocytopenia.

G Maschmeyer1, E Haralambie, W Gaus, W Kern, A W Dekker, H G De Vries-Hospers, W Sizoo, W König, F Gutzler, S Daenen.   

Abstract

In a randomized multicenter study, ciprofloxacin and norfloxacin, each in two different dose regimens and in combination with non-absorbable antimycotics, were administered to 51 patients with acute leukaemia undergoing aggressive remission induction chemotherapy for infection prevention. Both drugs showed an effective elimination of gram-negative potential pathogens and Staphylococcus aureus not affecting the anaerobic flora of the gastrointestinal tract. A low incidence of side effects and a satisfactory patient compliance could be observed. A daily dosage of 1,000 mg ciprofloxacin or 800 mg norfloxacin is recommended for infection prevention in severely granulocytopenic patients.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3286509     DOI： 10.1007/bf01644312

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


  29 in total

1.  Co-trimoxazole versus non-absorbable antibiotics in acute leukaemia.

Authors:  J G Watson; B Jameson; R L Powles; T J McElwain; D N Lawson; I Judson; G R Morgenstern; H Lumley; H E Kay
Journal:  Lancet       Date:  1982-01-02       Impact factor: 79.321

2.  Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens.

Authors:  S C Schimpff; V M Young; W H Greene; G D Vermeulen; M R Moody; P H Wiernik
Journal:  Ann Intern Med       Date:  1972-11       Impact factor: 25.391

3.  Co-trimoxazole alone for prevention of bacterial infection in patients with acute leukaemia.

Authors:  I D Starke; P Donnelly; D Catovsky; J Darrell; S A Johnson; J M Goldman; D A Galton
Journal:  Lancet       Date:  1982-01-02       Impact factor: 79.321

4.  Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial.

Authors:  J E Karp; W G Merz; C Hendricksen; B Laughon; T Redden; B J Bamberger; J G Bartlett; R Saral; P J Burke
Journal:  Ann Intern Med       Date:  1987-01       Impact factor: 25.391

5.  Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

6.  Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect on fecal flora.

Authors:  M Rozenberg-Arska; A W Dekker; J Verhoef
Journal:  J Infect Dis       Date:  1985-07       Impact factor: 5.226

7.  Tissue distribution of ciprofloxacin following oral and intravenous administration.

Authors:  A Dalhoff; H U Eickenberg
Journal:  Infection       Date:  1985 Mar-Apr       Impact factor: 3.553

8.  A comparison of trimethoprim-sulfamethoxazole plus nystatin with gentamicin plus nystatin in the prevention of infections in acute leukemia.

Authors:  J C Wade; S C Schimpff; M T Hargadon; C L Fortner; V M Young; P H Wiernik
Journal:  N Engl J Med       Date:  1981-04-30       Impact factor: 91.245

9.  Causes of death in adults with acute leukemia.

Authors:  H Y Chang; V Rodriguez; G Narboni; G P Bodey; M A Luna; E J Freireich
Journal:  Medicine (Baltimore)       Date:  1976-05       Impact factor: 1.889

10.  Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia.

Authors:  J C Wade; S C Schimpff; K A Newman; P H Wiernik
Journal:  Ann Intern Med       Date:  1982-10       Impact factor: 25.391
View more
  15 in total

Review 1.  Selective decontamination in neutropenic patients.

Authors:  E Kurrle; T Schmeiser; W Kern
Journal:  Epidemiol Infect       Date:  1992-12       Impact factor: 2.451

2.  Defining the role of macrophages in local moxifloxacin tissue concentrations using biopsy data and whole-body physiologically based pharmacokinetic modelling.

Authors:  Andrea N Edginton; Gertrud Ahr; Stefan Willmann; Heino Stass
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 3.  Use of quinolones in the immunocompromised host.

Authors:  A G Maiche
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

4.  Clinical use of selective decontamination: the concept.

Authors:  D van der Waaij; W L Manson; J P Arends; H G de Vries-Hospers
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

5.  Ofloxacin versus trimethoprim-sulfamethoxazole for prevention of infection in patients with acute leukemia and granulocytopenia.

Authors:  W Kern; E Kurrle
Journal:  Infection       Date:  1991 Mar-Apr       Impact factor: 3.553

Review 6.  Use of the quinolones for the prophylaxis and therapy of infections in immunocompromised hosts.

Authors:  G Maschmeyer
Journal:  Drugs       Date:  1993       Impact factor: 9.546

7.  Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center.

Authors:  W V Kern; E Andriof; M Oethinger; P Kern; J Hacker; R Marre
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

8.  Streptococcal bacteremia in adult patients with leukemia undergoing aggressive chemotherapy. A review of 55 cases.

Authors:  W Kern; E Kurrle; T Schmeiser
Journal:  Infection       Date:  1990 May-Jun       Impact factor: 3.553

Review 9.  Selective decontamination in bone marrow transplant recipients.

Authors:  H F Guiot; R van Furth
Journal:  Epidemiol Infect       Date:  1992-12       Impact factor: 2.451

10.  Selective decontamination of the colon before elective colorectal surgery. West of Scotland Surgical Infection Study Group.

Authors:  E W Taylor; G Lindsay
Journal:  World J Surg       Date:  1994 Nov-Dec       Impact factor: 3.352
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.